Silence Therapeutics PLC Notice of AGM and Publication of Annual Report (2075E)

TIDMSLN

RNS Number : 2075E

Silence Therapeutics PLC

04 May 2017

Notice of AGM and publication of Annual Report

4 May 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its annual report and financial statements for the year ended 31 December 2016 ("Annual Report and Accounts"), including the Notice of Annual General Meeting ("AGM"), is available for download on the Company's website www.silence-therapeutics.com. The Annual Report and Accounts will be posted to shareholders on or before 9 May 2017.

The AGM will be held at 10am on Friday 2 June 2017, at the offices of Silence Therapeutics Plc, 72 Hammersmith Road, London, United Kingdom W14 8TH.

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated    Tel: +44 (0)20 
  Adviser and Joint Broker)               7523 8350 
  Henry Fitzgerald-O'Connor/Emma 
  Gabriel 
 Peel Hunt LLP (Joint Broker)            Tel: +44 (0)20 
  James Steel/Oliver Jackson              7418 8900 
 Media Enquiries:                        Tel: +44 (0) 
  FTI Consulting                          20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBGGDUDUGBGRS

(END) Dow Jones Newswires

May 04, 2017 07:05 ET (11:05 GMT)